TPTX News and Press, Turning Point Therapeutics Inc. From 06/03/22

Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...

Blueprint Medicines (NASDAQ:BPMC) rose 1.2% in premarket trading,  after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) came first to mind after Bristol agreed to buy TPTX. Blue...

Bristol Myers Squibb (NYSE:BMY) has entered into an agreement to acquire the clinical-stage precision oncology company Turning Point Therapeutics (TPTX) at a price of $76.00 per share in cash for a total consideration of $4.1B, the companies announced Friday. Turning Point (TPTX) shares have ...

Bristol Myers Squibb (NYSE:BMY) has entered into an agreement to acquire the clinical-stage precision oncology company Turning Point Therapeutics (TPTX) at a price of $76.00 per share in cash for a total consideration of $4.1B, the companies announced Friday. Turning Point (TPTX) shares have ...

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effect...

Turning Point Therapeutics press release (NASDAQ:TPTX): Q1 GAAP EPS of -$1.50 beats by $0.01. Revenue of $0.43M (-98.3% Y/Y). For further details see: Turning Point Therapeutics GAAP EPS of -$1.50 beats by $0.01, revenue of $0.43M

Granted Third Breakthrough Therapy Designation (BTD) for Repotrectinib for the treatment of patients with ROS1-positive Metastatic NSCLC who have been Previously Treated with One ROS1 TKI and who have not Received Prior Platinum-Based Chemotherapy Reported Positive Topline...

Turning Point Therapeutics (NASDAQ:TPTX) on Tuesday said the U.S. Food and Drug Administration (FDA) granted a third Breakthrough Therapy designation to the company's lead drug candidate repotrectinib for the treatment of non-small cell lung cancer (NSCLC) in a certain, specific indicati...

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the U.S. Food and Drug Administration (FDA) granted an eighth regu...

Turning Point Therapeutics (NASDAQ:TPTX) has licensed LM-302 from LaNova Medicines, an antibody drug conjugate (ADC) that could potentially treat gastric, gastroesophageal junction, and pancreatic cancer. LM-302, which will now be known as PX-4589, is in phase 1. PX-7589 targets Claudin1...